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associated with plasma fibrin clot properties 
and thrombin generation in patients with AF.
Methods We studied 100 patients with docu‑
mented nonvalvular AF, derived from the cohort 
described in detail elsewhere.9 Briefly, the ex‑
clusion criteria were: current anticoagulation, 
myocardial infarction or venous thromboembo‑
lism within the preceding 3 months, malignan‑
cy, acute infection, kidney failure requiring di‑
alysis, and liver cirrhosis. ORBIT (hypertension, 
abnormal renal / liver function, stroke, bleeding 
history or predisposition, labile international 
normalized ratio, elderly [>65 years], drugs / al‑
cohol concomitantly),10 HEMORR2HAGES (he‑
patic or renal disease, ethanol abuse, malignan‑
cy, older [aged >75], reduced platelet count, re‑
bleeding risk, hypertension [uncontrolled], ane‑
mia, genetic CYP 2C9 polymorphisms, excessive 
fall risk, stroke / TIA history),11 HAS ‑BLED,12 
and modified HAS ‑BLED13 scores were used to 
evaluate bleeding risk. The study protocol was 
approved by the University Ethics Committee.
Standard assay techniques were used in rou‑
tine laboratory investigations. N ‑terminal pro‑
‑B‑type natriuretic peptide (NT ‑proBNP) levels 
were measured using an immunoassay (Roche 
Diagnostics, Mannheim, Germany). We de‑
termined plasma tissue ‑type plasminogen ac‑
tivator antigen (tPA, Diagnostica Stago, As‑
nières‑sur‑Seine, France), plasminogen ac‑
tivator inhibitor‑1 antigen (PAI‑1, American 
Diagnostica, Stamford, Connecticut, United 
States), thrombin ‑activatable fibrinolysis in‑
hibitor (Chromogenix, Lexington, Massachu‑
setts, United States), and von Willebrand fac‑
tor antigen (Diagnostica Stago). Chromogenic 
Introduction Clinical schemas largely 
based on age and comorbidities, in particu‑
lar the CHA2DS2‑VASc and HAS ‑BLED (hyper‑
tension, abnormal renal/liver function, stroke, 
bleeding history or predisposition, labile inter‑
national normalized ratio, elderly [>65 years], 
drugs / alcohol concomitantly) scores, have been 
reported to predict thromboembolism or bleed‑
ing, respectively, in patients with atrial fibrilla‑
tion (AF). However, current European Society of 
Cardiology guidelines do not recommend any 
preferred scoring system to predict major bleed‑
ing but rather suggest identifying and correct‑
ing modifiable bleeding risk factors.1 Several bio‑
markers have been investigated,2 and currently 
some of them may be incorporated into bleed‑
ing risk assessment.3
Fibrin constitutes a key protein component 
of thrombi causing ischemic stroke.4 It has been 
shown that formation of compact clot networks, 
evidenced by low fibrin clot permeability, is an in‑
dependent predictor of both thromboembolic 
events and major bleedings in patients with atri‑
al fibrillation (AF) on oral anticoagulation. More‑
over, low permeability and HAS ‑BLED score of 
at least 3 had a predictive value for major bleeds.5 
Similar observations have been made for patients 
on rivaroxaban.6 Clot lysis has been found to be 
prolonged in patients with AF without any im‑
pact of CHA2DS2‑VASc and HAS ‑BLED scores.
7 
It remains unclear whether fibrin ‑related pro‑
thrombotic biomarker(s) added to a scoring sys‑
tem based on clinical risk factors can result in 
more accurate risk assessment across different 
AF populations.8
In this preliminary report, we investigat‑
ed whether clinical bleeding risk scores are 
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higher in patients with ORBIT bleeding score 
of at least 4 and 3 compared with ORBIT bleed‑
ing score of 0 to 2 (mean [SD], 7.0 [0.8] cm2×10‑9 
vs  7.3 [0.9]  cm2×10‑9 vs 6.5 [0.7]  cm2×10‑9; 
P = 0.002 and P = 0.048, respectively).
No associations of CLT and Ks with HEMOR‑
R2HAGES and HAS ‑BLED and modified HAS‑
‑BLED scores were observed in patients with AF.
Multiple linear regression adjusted for age, 
body mass index, and fibrinogen showed that 
ORBIT bleeding score (β = –0.17), PAI‑1 (β = 0.31), 
tPA (β = 0.18), and NT ‑proBNP (β = 0.42) were 
the independent predictors of CLT (R2 = 0.40) 
in the  whole group. In the  multiple regres‑
sion model, ORBIT bleeding score (β = 0.22), 
PAI‑1 (β = –0.35) and plasminogen (β = 0.22) 
were the independent predictors of Ks (R
2 = 0.29) 
in the study group.
Discussion This study demonstrates that 
the 5‑element ORBIT bleeding score which 
has been reported to have better ability to 
predict major bleeding in patients with AF 
as compared with HAS ‑BLED and ATRIA risk 
scores,10,14 is associated with enhanced fibrino‑
lysis and looser clot structure, which renders it 
prone to fragmentation. This finding extends 
our previous studies regarding plasma fibrin 
clot density and lysability in patients with 
AF.4, 5 We did not observe any association be‑
tween bleeding risk assessed by ORBIT, HEM‑
ORR2HAGES, HAS ‑BLED, modified HAS ‑BLED 
scores and thrombin generation, fibrinolytic 
proteins, and NT ‑proBNP. We observed that 
the highest ORBIT bleeding score was associ‑
ated with impaired kidney function and use of 
aspirin or clopidogrel that have been report‑
ed to unfavorably alter fibrin structure and 
function and also predispose to bleeding.4 ,9 
The exact mechanisms underlying these ob‑
servations remain to be established. Our study 
supports the concept of a complex clinical and 
biomarker ‑based approach in the bleeding risk 
assessment in patients with AF regarding mod‑
erate prediction using schemas based only on 
age and comorbidities.5,15
Our study has several limitations. The size 
of the study was limited especially in subgroup 
analyses. All laboratory measurements were de‑
termined once and changes over time cannot be 
excluded. Two biomarkers, GDF‑15 and tropo‑
nin, were not measured in the whole group and 
were not analyzed. Finally, statistical associa‑
tions reported here do not necessarily indicate 
a direct cause ‑effect relationship. We did not col‑
lect follow ‑up data, therefore, the actual bleed‑
ing rate in this group is unknown.
This hypothesis ‑generating report suggests 
that tendency to form looser and more lysable 
fibrin clots can be observed in patients with high 
bleeding risk assessed by ORBIT score. Further 
studies are needed to corroborate these results.
assays were used to measure α2‑antiplasmin 
and plasminogen (Diagnostica Stago). Fibrin‑
ogen was determined using the Clauss assay. 
Calibrated automated thrombography (Throm‑
binoscope BV, Maastricht, the Netherlands) was 
used to measure endogenous thrombin poten‑
tial as described.9 Fibrin clot permeability was 
measured using a pressure ‑driven system as 
described previously.9 A permeation coefficient 
(Ks), which indicates the pore size in the fiber 
network (higher values indicate looser fibrin 
structure), was calculated.
Clot lysis time (CLT) was defined as the time 
required for change from the  midpoint 
of the clear ‑to ‑maximum ‑turbid transition, 
to the final plateau phase at 405 nm, induced 
by 32 ng/ml tPA (Boehringer Ingelheim, In‑
gelheim, Germany).5 All measurements were 
performed by technicians blinded to the sam‑
ple status (inter‑and intra ‑assay coefficients 
of variation <7%).
Statistical analysis Data were presented as 
mean (SD) or median (interquartile range [IQR]), 
as appropriate. Normality was checked using 
the Shapiro –Wilk test. The t test or the Mann–
Whitney test were used to test differences be‑
tween 2 groups as appropriate. Means between 
the 3 groups were compared by 1‑way analysis 
of variance followed by the Tukey post ‑hoc test. 
Medians were analyzed by the Kruskal–Wallis 
test followed by the test for multiple compari‑
sons of mean rank. Correlations were assessed 
by the Pearson or Spearman test, as appropri‑
ate. Categorical variables were analyzed using 
the χ2 test or the Fisher exact tests. A P value of 
less than 0.05 was considered significant. Sta‑
tistical analyses were performed using STA‑
TISTICA version 13 (Statsoft Inc, Tulsa, Okla‑
homa, United States).
Results The data of patients with AF are pre‑
sented in TABLE 1 and in Supplementary material, 
TABLE 1. The mean (SD) ORBIT, HEMORR2HAG‑
ES, HAS ‑BLED, and modified HAS ‑BLED scores 
were 1.78 (1.48), 1.43 (1.14), 2.07 (1.12), and 
2.70 (1.16), respectively. A high bleeding risk 
defined as ORBIT score of at least 4, HEMOR‑
R2HAGES score of at least 4, HAS ‑BLED score 
of at least 3, and modified HAS ‑BLED score 
of at least 3 was found in 13%, 7%, 33%, and 
58% patients, respectively.
Patients with ORBIT bleeding score of at least 
4 were older, had higher prevalence of chronic 
kidney disease stage 3, anemia, previous seri‑
ous bleeding, and use of antiplatelets. This high‑
‑risk group had 20.8% shorter CLT (median [IQR], 
80 [78–92] min vs 101 [89–118] min; P = 0.027), 
compared with those with ORBIT bleeding score 
of 0 to 2. There was no difference between CLT 
in the group with ORBIT bleeding score 3 and 
at  least 4 (P = 0.28). Ks was 7.7% and 12.3% 
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SUPPLEMENTARY MATERIAL 
Supplementary material is available at www.mp.pl/kardiologiapolska.
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